中文

2010-2-5
CPGJ Selected to be Intellectual Property Pilot Unit
2009-12-14
A new chapter in Biopharmaceuticals -The Collaboration between Chinese and Brazilian Pharmaceutical Enterprises
2009-8-21
CPGJ was awarded the Leader & Contributor of Science and Technology in the 10th Anniversary of Focus in Zhangjiang Selection Activity
2009-6-23
YISAIPU: Top 10 Innovations
2009-5-30
Model Unit

What's monoclonal antibody (mAB)?
monoclonal antibody (mAB) ?A single type of antibody that is directed against a specific epitope (antigen, antigenic determinant) and is produced by a single clone of B cells or a single hybridoma cell line, which is formed by the fusion of a lymphocyte cell with a myeloma cell. Some myeloma cells synthesize single antibodies naturally.

 




CPGJ is Focusing on biopharmaceutical products development,manufacturing,
and marketing,in china and in the world.

CPGJ targets on producing therapeutic humanized/human antibodies,vaccines,and diagnostic products for unmet medical needs,in cancer and autoimmune diseases.


 
  Yisaipu

DESCRIPTION
Proprietary Name:  Recombinant Human Necrosis Factor-αReceptorII:IgG Fc (rhTNFR:Fc) Fusion Protein for Injection
Brand Name:   Yisaipu
Composi


No.399 Libing Road,Zhangjiang Hi-tech Park,
Shanghai 201203,P.R.China
Tel : 86-021-50791399
Fax:86-021-58553335


  Copyright 2002-2006 Shanghai CP Guojian Pharmaceutical Co.,Ltd.